Clinical Trial Update: Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a frontline combination CAR-T cell therapy for multiple myeloma or plasmacytoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasmacytoma

Drugs mentioned

• Frontline Combination CAR-T Cell Therapy

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Multiple Myeloma, Plasmacytoma | Phase 1, Phase 2 | Status: RECRUITING